Edgewise Therapeutics, Inc.
edgewisetx.comWhat Do They Do?
Develops small-molecule drug candidates for patients with muscular dystrophies and serious cardiac diseases.
10-K for FY2025, filed Feb 26, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$57.3MView ↗
- ▲ +59% (Loss)
- vs −$36.1M in Q2 FY2025
-
Jul 13, 2026
Completed the sale of sevasemten and the muscular dystrophy business
Servier paid $1.55 billion upfront, with up to $1.1 billion in additional milestone payments.
Sources
8-K, filed Jul 13, 2026
On July 10, 2026, Edgewise Therapeutics, Inc. (the “Company”) completed the previously announced acquisition of the Company’s sevasemten…View ↗
-
Jun 1, 2026
Agreed to sell sevasemten and the muscular dystrophy business
The agreement provided for $1.55 billion upfront and up to $1.1 billion in milestone payments.
Sources
8-K, filed Jun 1, 2026
BOULDER, Colo., [June 1, 2026] — Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today…View ↗
Who Do They Compete With?
Competes with Sarepta Therapeutics, Nippon Shinyaku, PTC Therapeutics, Solid Biosciences, Genethon, Dyne Therapeutics, Avidity Biosciences, REGENXBIO, Wave Life Sciences, Entrada Therapeutics, Vertex, Capricor Therapeutics, Satellos Bioscience, Bristol-Myers Squibb, Cytokinetics, Imbria Pharmaceuticals, Lexicon Pharmaceuticals, Celltrion, and Braveheart Bio
10-K for FY2025, filed Feb 26, 2026In addition, there are four exon skipping drugs which are marketed under an accelerated approval pathway from the FDA: EXONDYS 51…View ↗
Loading...
